ADMA Biologics Inc $ADMA Shares Bought by Advantage Alpha Capital Partners LP

Key Points

• Advantage Alpha Capital Partners LP increased its stake in ADMA Biologics by 53.3%, owning 106,075 shares valued at approximately $2.1 million at the end of the most recent quarter.
• ADMA Biologics reported earnings of $0.15 per share for the latest quarter, slightly exceeding analysts' expectations of $0.14, with a revenue increase of 13.8% compared to the same period last year.
• ADMA's stock has a consensus rating of "Buy" with a target price of $27.67, and it is currently trading around $17.10, reflecting a downward movement of 1.2% in recent sessions.

Advantage Alpha Capital Partners LP boosted its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 53.3% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 106,075 shares of the biotechnology company's stock after acquiring an additional 36,893 shares during the period. Advantage Alpha Capital Partners LP's holdings in ADMA Biologics were worth $2,105,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Skandinaviska Enskilda Banken AB publ acquired a new position in ADMA Biologics during the first quarter worth $35,000. Tsfg LLC acquired a new position in ADMA Biologics during the first quarter worth $51,000. Brooklyn Investment Group raised its position in ADMA Biologics by 28,655.6% during the first quarter. Brooklyn Investment Group now owns 2,588 shares of the biotechnology company's stock worth $51,000 after acquiring an additional 2,579 shares during the period. Harvest Fund Management Co. Ltd acquired a new position in ADMA Biologics during the first quarter worth $52,000. Finally, Farther Finance Advisors LLC raised its position in ADMA Biologics by 1,149.1% during the first quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 2,505 shares during the period. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Trading Down 1.2%

Shares of ADMA opened at $17.10 on Friday. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21. ADMA Biologics Inc has a 12-month low of $13.50 and a 12-month high of $25.67. The firm has a 50-day moving average price of $17.97 and a 200 day moving average price of $18.87. The firm has a market capitalization of $4.08 billion, a P/E ratio of 19.88 and a beta of 0.38.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.01. The company had revenue of $121.98 million during the quarter, compared to analyst estimates of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. ADMA Biologics's revenue was up 13.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.13 earnings per share. Sell-side analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Raymond James Financial upped their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research report on Thursday, May 8th. Wall Street Zen lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. One research analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $27.67.

Insider Transactions at ADMA Biologics

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 20,000 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $20.96, for a total transaction of $419,200.00. Following the sale, the director owned 94,830 shares of the company's stock, valued at approximately $1,987,636.80. This trade represents a 17.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Steve Elms sold 194,749 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the transaction, the director owned 87,330 shares in the company, valued at approximately $1,767,559.20. This trade represents a 69.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 455,621 shares of company stock valued at $9,461,633. 3.50% of the stock is currently owned by corporate insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.